Research Article


DOI :10.26650/IUITFD.2020.0037   IUP :10.26650/IUITFD.2020.0037    Full Text (PDF)

KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY

Mustafa Murat ÖzbalakIşıl Erdoğan ÖzünalSelin BerkTuğrul ElverdiAyşe SalihoğluAhmet Emre EşkazanEzgi Pınar ÖzbalakMuhlis Cem ArŞeniz ÖngörenZafer BaşlarYıldız AydınSeda EkizoğluAsuman ÇelebiAyşe Nur BuyruTeoman Soysal

Objective: Our study was performed on 49 chronic lymphocytic leukemia (CLL) patients followed in the outpatient clinic of the Istanbul University Cerrahpasa Medical Faculty Department of Hematology. We aimed to analyze the relationship between autoimmune phenomena and CLL. Methods: Twenty-five CLL patients with and 24 CLL patients without autoimmune phenomenon were included. Thirty-two of them were male and 17 were female. No statistically significant difference in the median age at diagnosis (60 vs 64) and in the median follow-up time (59 months vs 71 months) was detected. The initial diagnostic parameters were similar. Results: In our autoimmune phenomenon cohort, the most frequent autoimmune disease was autoimmune hemolytic anemia (AIHA) followed by immune thrombocytopenia (ITP) and pure red cell aplasia (PRCA). The direct antiglobulin positivity at the time of diagnosis was increased in the autoimmune phenomenon group (p=0.024). Additionally, the stage of CLL in patients of the autoimmune phenomenon group was more advanced than the other group (p=0.04). Although the number of autoimmune phenomena was not high enough, the CD38 positive cell ratio over 30% in the peripheral blood was more frequent in PRCA group (p=0.008). Conclusion: We could not determine a relationship between autoimmunity in CLL and KIR genotypes. We believe that a new study in a larger cohort with superior technical conditions should be planned to find accurate responses to our study.

DOI :10.26650/IUITFD.2020.0037   IUP :10.26650/IUITFD.2020.0037    Full Text (PDF)

KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR GEN DÜZEYLERİ VE OTOİMMÜN OLAYLAR İLE İLİŞKİSİ

Mustafa Murat ÖzbalakIşıl Erdoğan ÖzünalSelin BerkTuğrul ElverdiAyşe SalihoğluAhmet Emre EşkazanEzgi Pınar ÖzbalakMuhlis Cem ArŞeniz ÖngörenZafer BaşlarYıldız AydınSeda EkizoğluAsuman ÇelebiAyşe Nur BuyruTeoman Soysal

Amaç: İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Hematoloji Polikliniği’nde takip edilen 49 Kronik Lenfositik Lösemi (KLL) hastası çalışmaya dahil edilmiştir. Çalışmanın amacı, çeşitli otoimmün hastalıklar ile ilişkisi gösterilmiş olan Killer Immunoglobuline Like Receptor (KIR) gen düzeylerini, otoimmün olay gözlenmiş ve gözlenmemiş KLL hasta grupları arasında karşılaştırmaktır. Gereç ve Yöntem: Bu doğrultuda otoimmün olay gözlenmiş olan 25 ve otoimmün olay gözlenmemiş 24 KLL hastası çalışmaya dahil edilmiştir. Hastaların 32’si erkek, 17’si kadındır. Otoimmün hastalık gözlenen grup ile otoimmün olay gözlenmeyen KLL grubu arasında tanı anındaki yaş (60 vs 64) ve ortanca takip süresi (59 ay vs 71 ay), tanı anındaki parametreleri istatistiki olarak benzerdir. Bulgular: Gözlenen en sık otoimmün olay otoimmün hemolitik anemi (OİHA) iken onu immün trombositopeni (İTP) ve saf eritroid aplazi (PRCA) takip etmiştir. Otoimmün olay gözlenmiş hastaların tanı anında direkt antiglobulin testi pozitiflik oranı, otoimmün olay gözlenmemiş KLL hastalarına göre artmış olduğu gözlenmiştir (p=0.024). Ayrıca otoimmün olay gözlenen hastaların tanı anında KLL hastalık evrelerinin daha ileri olduğu görülmüştür (p=0.04). Otoimmün olaylar kendi aralarında değerlendirildiğinde ise, sayı az olmasına karşın, PRCA’da çevresel kanda CD38 pozitif hücre oranının %30’un üstünde olma sıklığının arttığı gözlenmiştir (p=0.008). Sonuç: Çalışmamızda KIR genlerinin otoimmün olaylarla ilişkisi incelendiğinde, otoimmünite gözlenmeyen gruba göre herhangi bir istatistiki fark tespit edilememiştir. Daha iyi teknik şartlarda yeni çalışmalar yapılmasında fayda vardır. 


PDF View

References

  • 1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56. Epub 2008/01/25. [CrossRef] google scholar
  • 2. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99(3):1023-9. Epub 2002/01/25. [CrossRef] google scholar
  • 3. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33(2):230-9. Epub 2006/04/18. [CrossRef] google scholar
  • 4. Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica 2011;96(5):752-61. Epub 2011/01/19. [CrossRef] google scholar
  • 5. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101(4):1262-9. Epub 2002/10/31. [CrossRef] google scholar
  • 6. Hodgson K, Ferrer G, Pereira A, Moreno C, Montserrat E. Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 2011;154(1):14-22. Epub 2011/05/04. [CrossRef] google scholar
  • 7. Akpinar S. Kronik Lenfositik Lösemide KIR gen polimorfizmi [Yandal Uzmanlık Tezi]. Edirne: Trakya Üniversitesi Tıp Fakültesi; 2013. google scholar
  • 8. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011;132(3):315-25. Epub 2011/01/11. [CrossRef] google scholar
  • 9. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 2009;8(23):2211-20. Epub 2009/11/20. [CrossRef] google scholar
  • 10. Nourse JP, Lea R, Crooks P, Wright G, Tran H, Catalano J, et al. The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagul Fibrinolysis 2012;23(1):45-50. Epub 2011/10/26. [CrossRef] google scholar
  • 11. Shastry A, Sedimbi SK, Rajalingam R, Rumba I, Kanungo A, Sanjeevi CB. Different KIRs confer susceptibility and protection to adults with latent autoimmune diabetes in Latvian and Asian Indian populations. Ann N Y Acad Sci 2008;1150:133-8. Epub 2009/01/06. [CrossRef] google scholar
  • 12. Salim PH, Jobim M, Jobim LF, Xavier RM. Autoimmune rheumatic diseases and their association with killer immunoglobulin-like receptor genes. Rev Bras Reumatol. 2011;51(4):351-6, 62-4. Epub 2011/07/23. doi: S0482-50042011000400007 google scholar
  • 13. Karabon L, Jedynak A, Giebel S, Wolowiec D, Kielbinski M, Woszczyk D, et al. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens 2011;78(2):129-38. Epub 2011/07/06. [CrossRef] google scholar
  • 14. Junevik K, Werlenius O, Hasselblom S, Jacobsson S, Nilsson-Ehle H, Andersson PO. The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL). Ann Hematol 2007;86(2):89-94. Epub 2006/10/18. [CrossRef] google scholar
  • 15. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34. Epub 1975/08/01. [CrossRef] google scholar
  • 16. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48(1):198-206. Epub 1981/07/01. [CrossRef] google scholar
  • 17. Olerup. KIR genotyping [11.07.2015]. Available from: http:// www.olerup-ssp.com/productfiles/interpretation_tables/ KIR%20Genotyping%202013%2078R%20R01.pdf. google scholar
  • 18. Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992;3(2):171-2. Epub 1992/02/01. [CrossRef] google scholar
  • 19. Tosti S, Caruso R, D’Adamo F, Picardi A, Ali Ege M, Girelli G, et al. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol 1992;65(5):238-9. Epub 1992/11/01. [CrossRef] google scholar
  • 20. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995;91(2):341-4. Epub 1995/10/01. [CrossRef] google scholar
  • 21. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11(1):7-13. Epub 2009/12/18. [CrossRef] google scholar
  • 22. Borthakur G, O’Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol 2007;136(6):800-5. Epub 2007/03/08. [CrossRef] google scholar
  • 23. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111(4):1820-6. Epub 2007/12/07. [CrossRef] google scholar
  • 24. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986;39(7):713-6. Epub 1986/07/01. [CrossRef] google scholar
  • 25. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141(5):615-21. [CrossRef] google scholar
  • 26. Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006;91(12):1689-92. Epub 2006/12/06. google scholar
  • 27. Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95(9):2786-92. Epub 2000/04/26. [CrossRef] google scholar
  • 28. Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010;116(23):4771-6. Epub 2010/08/26. [CrossRef] google scholar
  • 29. Visco C, Ruggeri M, Laura Evangelista M, Stasi R, Zanotti R, Giaretta I, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111(3):1110-6. Epub 2007/11/08. [CrossRef] google scholar
  • 30. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105(5):2007-15. Epub 2004/07/31. [CrossRef] google scholar
  • 31. Galletti J, Canones C, Morande P, Borge M, Oppezzo P, Geffner J, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol. 2008;181(5):3674-83. Epub 2008/08/21. [CrossRef] google scholar
  • 32. von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG. CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol 2004;15(6):853-7. Epub 2004/05/21. [CrossRef] google scholar
  • 33. Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 2018;132(9):892-902. Epub 2018/07/13. [CrossRef] google scholar
  • 34. Bachanova V, Weisdorf DJ, Wang T, Marsh SGE, Cereb N, Haagenson MD, et al. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 2019;25(5):949-54. Epub 2018/12/31. doi: 10.1016/j.bbmt.2018.12.763. [CrossRef] google scholar
  • 35. Williams F, Meenagh A, Sleator C, Cook D, Fernandez-Vina M, Bowcock AM, et al. Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol 2005;66(7):836-41. Epub 2005/08/23. [CrossRef] google scholar
  • 36. Romero V, Zuniga J, Azocar J, Clavijo OP, Terreros D, Kidwai H, et al. Genetic interactions of KIR and G1M immunoglobulin allotypes differ in obese from non-obese individuals with type 2 diabetes. Mol Immunol. 2008;45(14):3857-62. Epub 2008/07/18. [CrossRef] google scholar
  • 37. Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladman DD. KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens 2007;69 Suppl 1:106-8. Epub 2007/04/21. [CrossRef] google scholar
  • 38. Lowe DP, Cook MA, Bowman SJ, Briggs DC. Association of killer cell immunoglobulin-like receptors with primary Sjogren’s syndrome. Rheumatology (Oxford) 2009;48(4):359-62. Epub 2009/02/03. [CrossRef] google scholar
  • 39. Jiao YL, Zhang BC, You L, Li JF, Zhang J, Ma CY, et al. Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. J Clin Immunol 2010;30(6):840-4. Epub 2010/07/24. [CrossRef] google scholar
  • 40. Fusco C, Guerini FR, Nocera G, Ventrella G, Caputo D, Valentino MA, et al. KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. J Neuroimmunol 2010;229(1-2):232-7. Epub 2010/09/10. [CrossRef] google scholar
  • 41. Cosentini E, Gargiulo L, Bruno P, Lastraioli S, Risitano A, Camerlingo R, et al. Killer immunoglobulin-like receptors (KIR) and their HLA-ligands in Italian paroxysmal nocturnal haemoglobinuria (PNH) patients. Tissue Antigens 2012;80(4):322-7. Epub 2012/07/19. [CrossRef] google scholar
  • 42. Taintor AR, Leiferman KM, Hashimoto T, Ishii N, Zone JJ, Hull CM. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. J Am Acad Dermatol 2007;56(5 Suppl):S73-6. Epub 2007/04/17. [CrossRef] google scholar
  • 43. Seymour LA, Nourse JP, Crooks P, Wockner L, Bird R, Tran H, et al. The presence of KIR2DS5 confers protection against adult immune thrombocytopenia. Tissue Antigens. 2014;83(3):154-60. Epub 2014/02/28. [CrossRef] google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Özbalak, M.M., Erdoğan Özünal, I., Berk, S., Elverdi, T., Salihoğlu, A., Eşkazan, A.E., Özbalak, E.P., Ar, M.C., Öngören, Ş., Başlar, Z., Aydın, Y., Ekizoğlu, S., Çelebi, A., Buyru, A.N., & Soysal, T. (2021). KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY. Journal of Istanbul Faculty of Medicine, 84(2), 227-236. https://doi.org/10.26650/IUITFD.2020.0037


AMA

Özbalak M M, Erdoğan Özünal I, Berk S, Elverdi T, Salihoğlu A, Eşkazan A E, Özbalak E P, Ar M C, Öngören Ş, Başlar Z, Aydın Y, Ekizoğlu S, Çelebi A, Buyru A N, Soysal T. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY. Journal of Istanbul Faculty of Medicine. 2021;84(2):227-236. https://doi.org/10.26650/IUITFD.2020.0037


ABNT

Özbalak, M.M.; Erdoğan Özünal, I.; Berk, S.; Elverdi, T.; Salihoğlu, A.; Eşkazan, A.E.; Özbalak, E.P.; Ar, M.C.; Öngören, Ş.; Başlar, Z.; Aydın, Y.; Ekizoğlu, S.; Çelebi, A.; Buyru, A.N.; Soysal, T. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 84, n. 2, p. 227-236, 2021.


Chicago: Author-Date Style

Özbalak, Mustafa Murat, and Işıl Erdoğan Özünal and Selin Berk and Tuğrul Elverdi and Ayşe Salihoğlu and Ahmet Emre Eşkazan and Ezgi Pınar Özbalak and Muhlis Cem Ar and Şeniz Öngören and Zafer Başlar and Yıldız Aydın and Seda Ekizoğlu and Asuman Çelebi and Ayşe Nur Buyru and Teoman Soysal. 2021. “KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY.” Journal of Istanbul Faculty of Medicine 84, no. 2: 227-236. https://doi.org/10.26650/IUITFD.2020.0037


Chicago: Humanities Style

Özbalak, Mustafa Murat, and Işıl Erdoğan Özünal and Selin Berk and Tuğrul Elverdi and Ayşe Salihoğlu and Ahmet Emre Eşkazan and Ezgi Pınar Özbalak and Muhlis Cem Ar and Şeniz Öngören and Zafer Başlar and Yıldız Aydın and Seda Ekizoğlu and Asuman Çelebi and Ayşe Nur Buyru and Teoman Soysal. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY.” Journal of Istanbul Faculty of Medicine 84, no. 2 (May. 2024): 227-236. https://doi.org/10.26650/IUITFD.2020.0037


Harvard: Australian Style

Özbalak, MM & Erdoğan Özünal, I & Berk, S & Elverdi, T & Salihoğlu, A & Eşkazan, AE & Özbalak, EP & Ar, MC & Öngören, Ş & Başlar, Z & Aydın, Y & Ekizoğlu, S & Çelebi, A & Buyru, AN & Soysal, T 2021, 'KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY', Journal of Istanbul Faculty of Medicine, vol. 84, no. 2, pp. 227-236, viewed 17 May. 2024, https://doi.org/10.26650/IUITFD.2020.0037


Harvard: Author-Date Style

Özbalak, M.M. and Erdoğan Özünal, I. and Berk, S. and Elverdi, T. and Salihoğlu, A. and Eşkazan, A.E. and Özbalak, E.P. and Ar, M.C. and Öngören, Ş. and Başlar, Z. and Aydın, Y. and Ekizoğlu, S. and Çelebi, A. and Buyru, A.N. and Soysal, T. (2021) ‘KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY’, Journal of Istanbul Faculty of Medicine, 84(2), pp. 227-236. https://doi.org/10.26650/IUITFD.2020.0037 (17 May. 2024).


MLA

Özbalak, Mustafa Murat, and Işıl Erdoğan Özünal and Selin Berk and Tuğrul Elverdi and Ayşe Salihoğlu and Ahmet Emre Eşkazan and Ezgi Pınar Özbalak and Muhlis Cem Ar and Şeniz Öngören and Zafer Başlar and Yıldız Aydın and Seda Ekizoğlu and Asuman Çelebi and Ayşe Nur Buyru and Teoman Soysal. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY.” Journal of Istanbul Faculty of Medicine, vol. 84, no. 2, 2021, pp. 227-236. [Database Container], https://doi.org/10.26650/IUITFD.2020.0037


Vancouver

Özbalak MM, Erdoğan Özünal I, Berk S, Elverdi T, Salihoğlu A, Eşkazan AE, Özbalak EP, Ar MC, Öngören Ş, Başlar Z, Aydın Y, Ekizoğlu S, Çelebi A, Buyru AN, Soysal T. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY. Journal of Istanbul Faculty of Medicine [Internet]. 17 May. 2024 [cited 17 May. 2024];84(2):227-236. Available from: https://doi.org/10.26650/IUITFD.2020.0037 doi: 10.26650/IUITFD.2020.0037


ISNAD

Özbalak, MustafaMurat - Erdoğan Özünal, Işıl - Berk, Selin - Elverdi, Tuğrul - Salihoğlu, Ayşe - Eşkazan, AhmetEmre - Özbalak, EzgiPınar - Ar, MuhlisCem - Öngören, Şeniz - Başlar, Zafer - Aydın, Yıldız - Ekizoğlu, Seda - Çelebi, Asuman - Buyru, AyşeNur - Soysal, Teoman. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY”. Journal of Istanbul Faculty of Medicine 84/2 (May. 2024): 227-236. https://doi.org/10.26650/IUITFD.2020.0037



TIMELINE


Submitted14.07.2020
Accepted06.01.2021
Published Online19.03.2021

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.